Pediatric Drug-Susceptible TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS**, **TB & Malaria**. **Stop TB Partnership/Global Drug Facility** licensed the TB Medicines Dashboard under a **Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License**.

Medicines	WHO Guidelines (DS-TB'17)	WHO Guidelines (Children & Adolescent '22)	EMLc submitted	EMLc (2021)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2023)	Global Fund ERP recommended	GDF Catalog
Ethambutol 25mg/mL oral liquid											
Ethambutol 50mg dispersible tablet											
Ethambutol 100mg dispersible tablet											
Ethambutol 100mg tablet											
Ethionamide 125mg dispersible tablet											
Isoniazid 50mg dispersible tablet											
Isoniazid 50mg/5mL oral liquid											

DS-TB: Drug-Susceptible TB EML: Essential Medicines List EOI: Expression of Interest ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: February 2023







Status
Yes
No

N/A

Ineligible for inclusion



Pediatric Drug-Susceptible TB Medicines Dashboard

This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria. Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Medicines	WHO Guidelines (DS-TB '17)	WHO Guidelines (Children & Adolescent '22)	EMLc submitted	EMLc (2021)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2023)	Global Fund ERP recommended	GDF Catalog
Isoniazid 100mg dispersible tablet											
Isoniazid 100mg tablet											
Isoniazid 300mg tablet/capsule											
Pyrazinamide 30mg/mL oral liquid											
Pyrazinamide 150mg dispersible tablet											
Rifampicin 20mg/mL oral liquid											
Rifampicin/Isoniazid 75/50 dispersible tablet											

DS-TB: Drug-Susceptible TB EML: Essential Medicines List **EOI:** Expression of Interest **ERP**: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: February 2023







Status Yes No

N/A

Ineligible for inclusion



Pediatric Drug-Susceptible TB Medicines Dashboard

This Dashboard has been developed by **Stop TB Partnership/Global Drug Facility** in collaboration with **USAID**, the **World Health Organization** and **The Global Fund to fight AIDS**, **TB & Malaria**. **Stop TB Partnership/Global Drug Facility** licensed the TB Medicines Dashboard under a **Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License**.

Medicines	WHO Guidelines (DS-TB '17)	WHO Guidelines (Children & Adolescent '22)	EMLc submitted	EMLc (2021)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (Feb 2023)	Global Fund ERP recommended	GDF Catalog	Status Yes No Ineligible for inclusion N/A
Rifampicin/Isoniazid/ Pyrazinamide 75/50/150mg dispersible tablet												

DS-TB: Drug-Susceptible TB

EML: Essential Medicines List **EOI:** Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

Version: February 2023







